The Effects of Sedatives on Tobacco Use Disorder Version 2
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 20 people enrolled
- Started
- 31 Jan 2023
- Ended
- 10 Dec 2025
- Type of study
- Interventional, 12 groups
- Treatments tested
- Ketamine
- Midazolam
- Dexmedetomidine
- Saline
- Record updated
- 1 April 2026
Who can take part
- Age
- 21 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Smokes cigarettes daily for at least 2 years
- Afternoon expired breath carbon monoxide at least 5 ppm or morning urinary cotinine at least 100 ng/ml
- Negative urine drug screen for psychoactive drugs and negative breath alcohol
Who cannot take part
- Use of drugs that would interact with study drug or increase risk of adverse events
- Have an unstable medical condition or stable medical condition that would interact with study drug or participation, including chronic pulmonary disease, coronary artery disease, current brain tumor, current increased intracranial pressure or impaired consciousness
- History of serious head trauma or neurological disorder (e.g., seizure disorder)
- Have any of the following: hypertension (i.e., systolic >140 mm Hg and/or diastolic >90 mm Hg on three separate measures; systolic >170 or diastolic > 110 on any occasion), pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic)
- Among women, pregnancy or lactation
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United States
About the trial
What the trial wants to find out
Double-blind, placebo-controlled, randomized mechanistic clinical trial to test an intravenous dose of either ketamine, midazolam, dexmedetomidine, or a placebo (saline) on cigarette smoking behavior, craving, and neural effects.
The 12 groups in the trial
- Saline first injection; ketamine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
Treatment: Ketamine and Saline
- Saline first injection; midazolam second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion midazolam at the second injection visit
Treatment: Midazolam and Saline
- Saline first injection; dexmedetomidine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
Treatment: Dexmedetomidine and Saline
- Ketamine first injection; Saline second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
Treatment: Ketamine and Saline
- Ketamine first injection; midazolam second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
Treatment: Ketamine and Midazolam
- Ketamine first injection; dexmedetomidine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
Treatment: Ketamine and Dexmedetomidine
- Midazolam first injection; Saline second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion placebo at the second injection visit.
Treatment: Midazolam and Saline
- Midazolam first injection; ketamine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
Treatment: Ketamine and Midazolam
- Midazolam first injection; dexmedetomidine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
Treatment: Midazolam and Dexmedetomidine
- Dexmedetomidine first injection; Saline second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
Treatment: Dexmedetomidine and Saline
- Dexmedetomidine first injection; ketamine second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
Treatment: Ketamine and Dexmedetomidine
- Dexmedetomidine first injection; midazolam second injectionTreatment being tested
Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
Treatment: Midazolam and Dexmedetomidine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 April 2026